Clinical Trials Directory

Trials / Terminated

TerminatedNCT00523328

BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)

An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects With Rheumatoid Arthritis Who Previously Participated in Study 104RA203

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
72 (actual)
Sponsor
Biogen · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study is to observe the long-term treatment of BG9924

Detailed description

Extension study for 104RA203 (NCT 00458861)

Conditions

Interventions

TypeNameDescription
DRUGBG9924dosage administered as per Biogen-idec protocol

Timeline

Start date
2007-08-01
Primary completion
2008-10-01
Completion
2008-10-01
First posted
2007-08-31
Last updated
2016-01-21

Locations

4 sites across 4 countries: United States, Belgium, Canada, United Kingdom

Source: ClinicalTrials.gov record NCT00523328. Inclusion in this directory is not an endorsement.

BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861) (NCT00523328) · Clinical Trials Directory